ETRA
NASDAQ HealthcareElectra Therapeutics, Inc. - Common stock
Biotechnology
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
๐ Market Data
| Price | $8.64 |
|---|---|
| Volume | 166,475 |
| Market Cap | 542.31M |
| RSI (14-Day) | 45.1 |
| 52-Week High | $15.50 |
| 52-Week Low | $8.26 |
| Forward P/E | -4.81 |
๐ฏ Investment Strategy Scores
ETRA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (65/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Find ETRA in your text
Paste any article, transcript, or post โ the tool will extract ETRA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.